top line
Zepbound is the rebranded drug company Eli Lilly’s diabetes drug aimed at weight loss. currently available It was sold in U.S. pharmacies less than a month after receiving approval from the Food and Drug Administration, joining other popular weight loss drugs such as Ozempic and Wigovy that are facing shortages.
People who have commercial insurance but are not insured by Zepbound may also be eligible for payments … [+]
important facts
Zepbound, commonly referred to as tirzepatide, is a weekly injection intended for overweight adults who are obese or have at least one weight-related medical problem, such as type 2 diabetes or cardiovascular disease.
People who are obese can receive prescriptions for Zepbound in six different doses ranging from 2.5 milligrams to 15 milligrams and can be filled at retail stores or mail-order pharmacies. according to Eli Lilly.
Eli Lilly’s Commercial Savings Card program is designed to help adults without Zepbound coverage and is available at U.S. pharmacies.
People who have commercial insurance but are not insured by Zepbound was able to pay $550 — about half price List price $1,060 — for a one-month prescription.
On the other hand, commercial insurers who insure this drug; was able to pay $25 for a 1-month or 3-month prescription.
In clinical trials, 15 milligrams of Zepbound administered weekly lose weight Lose 22.5% (average 52 pounds for people with a median weight of 231 pounds) over 72 weeks.
Main background
Zepbound’s active ingredient, tirzepatide, was already FDA-approved and sold as Mounjaro, a once-weekly diabetes treatment, before it received FDA approval last month under the name Zepbound. Zepbound is a GLP-1 (glucagon-like peptide-1) receptor agonist that activates hormone receptors that reduce appetite and food intake. This drug also mimics the GIP (glucose-dependent insulinotropic polypeptide) hormone. release insulin Controls blood sugar levels after meals. In addition to Zepbound, the FDA has approved two other similar weight loss drugs, Wegovy and Saxenda, but the diabetes drug Ozempic, which is commonly prescribed to treat obesity, is not approved as a weight loss treatment. According to the FDA: About 70% of American adults are obese or overweight, and many who are overweight have a weight-related disease. Zepbound must be used with a low-calorie diet, and people taking this drug should increase physical activity, Eli Lilly Said.
amazing facts
When the FDA approved Zepbound last month, it said: it was unknown Whether the drug causes tumors such as thyroid cancer in humans. Now, Eli Lilly caveat The drug “may cause thyroid tumors, including thyroid cancer.”
References
Diabetes drug Munjaro expected to be approved soon as a weight loss drug: What you need to know and how it compares to similar drugs (Forbes)
A new weight loss drug could become the best-selling drug of all time. Who can afford it? (NBC News)
